Shareholder proposals targeting major pharmaceutical companies and resolutions looking into corporate spending on political activities are among those featuring in what is set to be another groundbreaking US proxy season for ESG.
Ahead of this year’s AGMs, the Interfaith Center on Corporate Responsibility (ICCR) co-ordinated the filing of proposals with nine pharmaceutical companies about their use of intellectual property. The companies at issue are AbbVie, Amgen, Bristol Myers Squibb, Eli Lilly and Company, Gilead Sciences, Johnson & Johnson, Merck & Co, Pfizer and Regeneron Pharmaceuticals.
In each case, ICCR member organizations ask the relevant company’s board ‘to . . .
Enjoy access to this and more – for free!
Log in or create your free My IR – Essentials account to:
- Get access to 3 free IR deep dives
- More than 100 pieces of insight, plus our exclusive CFO interviews
- Save favorites and get personalized content on your dashboard
- Enjoy 10% off all IR forums
